Guardant Health GH 深 滬
交易中 09-08 10:09:53 美东时间
163.31
+1.900
+1.18%
華盛通- 最 高166.69
- 今 開166.11
- 成交量 37.06万股
- 最 低 161.42
- 昨 收 161.41
- 總市值 2191.56万
- 52周最高 176.58
- 市盈率 靜 --
- 換手率 0.28%
- 52周最低 53.40
- 委 比 60.71%
- 總股本 0.00亿
- 歷史最高 181.07
- 量 比 3.12
- 振 幅 3.26%
- 歷史最低 15.81
- 每 手 1
- 風險率 31.64%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Cathie Wood's weekly recap: loads Rocket Lab, Block; cuts Palantir, Tempus AI
Cathie Wood’s Ark Invest leaned further into high-growth themes, including space, fintech, crypto, and biotechnology, during the last week while trimming several large technology and healthcare positi...
09-07 19:10
美股大行评级 | 最高735美元！戴尔科技绩后获11家大行上调目标价；MongoDB绩后分歧大，9家上调；4家下调；派拓网络、GitLab、美敦力获多家大行上调目标价
今日重点评级关注：Tigress Financial：维持Liftoff Mobile"买入"评级，目标价从39美元升至41美元；奥本海默：维持SpaceX"跑赢大市"评级，目标价从250美元升至280美元
09-03 13:50
Guardant Health shares are trading higher after the company announced that its Shield blood test for colorectal cancer screening will be covered in Carelon Healthcare Services clinical guidelines.
Guardant Health shares are trading higher after the company announced that its Shield blood test for colorectal cancer screening will be covered in Carelon Healthcare Services clinical guidelines.
09-02 01:50
Guardant Health loses patent judgment; ordered to pay $245M
A Delaware federal court issued final judgment in favor of TwinStrand BioSciences and the University of Washington, who accused Guardant Health (GH) of infringing two core patents related to TwinStran...
08-25 04:14
Guardant Health shares are trading lower after the U.S. District Court for the District of Delaware ruled in favor of TwinStrand and the University of Washington in their patent infringement lawsuit against the company.
Guardant Health shares are trading lower after the U.S. District Court for the District of Delaware ruled in favor of TwinStrand and the University of Washington in their patent infringement lawsuit against the company.
08-24 22:54
Insight Molecular Diagnostics to Host Virtual KOL Event on August 17, 2026: Moving Toward In-House Heart Transplanted Organ Rejection Testing
Insight Molecular Diagnostics Inc. (iMDx) will host a virtual KOL event on August 17, 2026, featuring Max Jacob Liebo, MD, Nick Ioannou, MD, MHA, and Josh Riggs to discuss the GraftAssure platform, which uses digital PCR technology for reliable dd-cfDNA results in transplant organ monitoring. The event will cover the FDA-reviewed GraftAssureDx test for kidney transplant rejection and its implications for heart transplants. iMDx aims to bring test...
08-11 20:05
美股大行评级 | Palantir、Snap、爵士制药获多家大行上调目标价；潜在涨幅176.34%！巴克莱维持Snap(SNAP)"超配"评级，目标价从15美元上调至16美元
今日重点评级关注：巴克莱：维持Snap"超配"评级，目标价从15美元升至16美元；Canaccord Genuity：维持阿梅雷斯克"买入"评级，目标价从59美元升至62美元
08-05 11:45
美股大行评级 | 潜在涨幅3586.64%！HC Wainwright上调Enlivex目标价至80美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Enlivex"买入"评级，目标价从20美元升至80美元；Canaccord Genuity：维持Pharming Group NV Sponsored ADR"买入"评级，目标价从37美元升至38美元
08-04 11:45
美股大行评级 | 最高400美元！亚马逊绩后获11家大行上调目标价；苹果绩后评级分歧大！3家上调，3家下调；德康医疗、万事达、神经分泌生物科学获多家大行上调目标价
今日重点评级关注：TD Cowen：维持加拿大鹅"买入"评级，目标价从13美元升至18美元；瑞银：维持吉登运动服"买入"评级，目标价从110美元升至111美元
08-03 11:38
财报速睇 | Guardant Health 2026财年Q2营收3.35亿美元，同比增长44.4%；归母净利润亏损1.20亿美元，同比亏损扩大20.0%
华盛资讯8月2日讯，Guardant Health公布2026财年Q2业绩，公司Q2营收3.35亿美元，同比增长44.4%，归母净利润亏损1.20亿美元，同比亏损扩大20.0%。
08-02 05:32
